×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Pfizer pays 3SBio $1.25B for PD-1xVEGF bispecific, joining red-hot race with BioNTech, Merck
Fierce Biotech
Pfizer made a splashy entrance late Monday, revealing it is paying $1.25 billion upfront and committing up to $4.8 billion in milestones for ex-...
1 month ago
Pfizer buys into PD-1/VEGF competition with 3SBio deal
BioPharma Dive
Pfizer buys into PD-1/VEGF competition with 3SBio deal. Pfizer will pay China's 3SBio $1.25 billion up front to access a cancer drug that works...
1 month ago
Pfizer Enters into Exclusive Licensing Agreement with 3SBio
Business Wire
Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese...
2 months ago
Pfizer licenses cancer bispecific antibody from Chinese developer 3SBio in $1.25 billion bid
BioProcess International
Pfizer has entered an exclusive licensing agreement with Chinese biologic developer 3SBio for the development, manufacturing, and commercialization of...
1 month ago
Pfizer in deal with China's 3SBio to license cancer drug candidate, take equity stake
Reuters
US drugmaker Pfizer (PFE.N) said it would license an experimental cancer treatment from China's 3SBio Inc (1530.HK), paying $1.25 billion upfront.
2 months ago
While institutions invested in 3SBio Inc. (HKG:1530) benefited from last week's 16% gain, individual investors stood to gain the most
Simply Wall Street
Key Insights 3SBio's significant individual investors ownership suggests that the key decisions are influenced by...
4 days ago
Pfizer strikes $1.25 billion licensing deal with Chinese biopharma 3SBIO
Medical Marketing and Media
Pfizer strikes $1.25 billion licensing deal with Chinese biopharma 3SBIO. The pharma giant entered an exclusive agreement with the Chinese...
1 month ago
Pfizer signs global licensing deal with 3SBio for bispecific antibody
Pharmaceutical Technology
Pfizer signs global licensing deal with 3SBio for bispecific antibody. Pfizer will pay $1.25 upfront, and 3SBio could earn up to $4.8bn in...
1 month ago
Chris Boshoff: Pfizer Enters Licensing Agreement with 3SBio for Next-Gen Bispecific Antibody
Oncodaily
Pfizer has entered into an exclusive licensing agreement with 3SBio Inc., focused on the global, ex-China, development and commercialization of a next-...
1 month ago
Pfizer Signs Experimental Drug Licensing Agreement With 3SBio
Yahoo Finance
In This Article: ... Pharmaceutical giant Pfizer Inc. PFE has signed a significant licensing agreement with China's 3SBio Inc. for an experimental...
1 month ago